Shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) have been assigned an average rating of “Buy” from the fifteen analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $52.91.

GBT has been the subject of several research reports. BidaskClub raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Cowen and Company reissued an “outperform” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a research report on Monday, August 14th. J P Morgan Chase & Co reissued an “overweight” rating and issued a $46.00 price target (up previously from $44.00) on shares of Global Blood Therapeutics in a research report on Tuesday, August 8th. ValuEngine raised shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th.

In other Global Blood Therapeutics news, Director Deval L. Patrick sold 27,053 shares of Global Blood Therapeutics stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the transaction, the director now directly owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Friday, July 21st. The stock was sold at an average price of $30.00, for a total transaction of $90,000.00. Following the transaction, the insider now directly owns 143,255 shares in the company, valued at $4,297,650. The disclosure for this sale can be found here. Insiders have sold a total of 33,053 shares of company stock worth $983,204 over the last ninety days. Insiders own 5.30% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parametric Portfolio Associates LLC boosted its holdings in Global Blood Therapeutics by 0.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,943 shares of the company’s stock worth $846,000 after acquiring an additional 284 shares during the last quarter. Legal & General Group Plc boosted its holdings in Global Blood Therapeutics by 10.1% during the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock worth $178,000 after acquiring an additional 440 shares during the last quarter. American International Group Inc. boosted its holdings in Global Blood Therapeutics by 24.1% during the 1st quarter. American International Group Inc. now owns 10,031 shares of the company’s stock worth $370,000 after acquiring an additional 1,945 shares during the last quarter. Alps Advisors Inc. boosted its holdings in Global Blood Therapeutics by 7.9% during the 2nd quarter. Alps Advisors Inc. now owns 39,366 shares of the company’s stock worth $1,077,000 after acquiring an additional 2,874 shares during the last quarter. Finally, Asset Management One Co. Ltd. purchased a new position in Global Blood Therapeutics during the 1st quarter worth $130,000. 86.07% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/09/global-blood-therapeutics-inc-gbt-given-average-recommendation-of-buy-by-brokerages.html.

Global Blood Therapeutics (NASDAQ:GBT) traded down 2.65% on Friday, hitting $27.60. 399,661 shares of the stock traded hands. The stock has a 50-day moving average price of $28.02 and a 200 day moving average price of $30.03. The company’s market cap is $1.21 billion. Global Blood Therapeutics has a 1-year low of $13.35 and a 1-year high of $41.15.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.06. During the same quarter last year, the company posted ($0.58) EPS. On average, analysts anticipate that Global Blood Therapeutics will post ($2.45) EPS for the current fiscal year.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.